Search
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.
Casein
go.drugbank.com/drugs/DB10516ApprovedCasein allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingPericiazine
go.drugbank.com/drugs/DB01608ApprovedIt is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. … It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected.
Omega-3-acid ethyl esters
go.drugbank.com/drugs/DB09539ApprovedInvestigationalOmega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849]. … Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower
Mixtures: ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI, ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICIMavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalmavorixafor is being investigated in these conditions. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.
Synonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal
Trichlormethiazide
go.drugbank.com/drugs/DB01021ApprovedVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedNisoldipine may be used in alone or in combination with other agents in the management of hypertension. … It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
International brands: Ji Ni Le Er, Di Yi XinBremelanotide
go.drugbank.com/drugs/DB11653Approved[A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.